B. Riley analyst Jeff Van Sinderen lowered the firm’s price target on Biote (BTMD) to $8 from $9 and keeps a Buy rating on the shares. The company’s Q1 revenue and adjusted EBITDA came in above expectations, the analyst tells investors in a research note. The firm trimmed the price target to reflect a reduced multiple.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD:
- Biote price target lowered to $4 from $6 at TD Cowen
- Biote Corp. Earnings Call: Mixed Results and Strategic Realignment
- Optimistic Growth Potential and Strategic Initiatives Justify Buy Rating Despite Challenges
- Biote price target lowered to $6 from $8 at Roth Capital
- Biote Corp. Reports Strong Q1 2025 Financial Results